Bicara Therapeutics Inc. (BCAX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$323.5M
Cash & Equivalents
$37.5M
Quarterly Burn Rate
26 mo
Est. Cash Runway
$1,418M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04429542 Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced ... PHASE1 Recruiting 292

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BCAX.

SEC EDGAR Filings

All SEC filings for Bicara Therapeutics Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.